Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NDC-0524
- Development stage
- Unknown
- Lead developer
- Nitrase Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
NDC-0524 is a first-in-class monoclonal antibody developed by Nitrase Therapeutics for the treatment of Parkinson's disease. It is designed with high selectivity for the nitrated form of alpha-synuclein, a post-translationally modified version of the protein that is implicated in the pathogenesis of Parkinson's. By binding to and neutralizing secreted, nitrated synuclein, NDC-0524 aims to prevent the cell-to-cell transmission of pathology from diseased neurons to healthy ones, potentially slowing disease progression. Preclinical models have demonstrated that the antibody can reduce harmful protein aggregates by as much as 88%. As of early 2026, the drug has transitioned into clinical development following the planned initiation of a Phase 1/2a trial in late 2025.
- Other names
- Nitrated alpha-synuclein monoclonal antibody
02
Targets
n-α-syn (Nitrated α-synuclein)
Beyond the preview
Go deeper on NDC-0524.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NDC-0524.